Hypertension is the major modifiable risk factor for fatal, nonfatal strokes and other vascular diseases. In a pooled analysis of 61 prospective studies including about one million individuals, the reported risk of stroke increased progressively with blood pressure from values as low as 115/75 mm/Hg. Each increment of 20/10 mm/Hg doubles the risk of cardiovascular disease and such a correlation is consistent at all ages. Blood pressure lowering strongly reduces the risk of either first stroke or recurrent stroke but the possibility that specific drugs may prevail over others for protection from stroke remains unclear. There is some evidence that specific classes of antihypertensive drugs have different effects and/or their pharmacological actions differ in patient subgroups. Currently, there are five classes of first-line blood pressure lowering drugs: diuretics, beta-blockers, calcium channel blockers, angiotensin-converting inhibitors and angiotensin II receptor blockers. This review evaluates the development of antihypertensive therapies and the latest studies of arterial hypertension and stroke prevention.
Keywords: Stroke prevention, risk factors, hypertension
The Pathophysiological Basis of Renal Nerve Ablation for the Treatment of Hypertension
Current Vascular Pharmacology A New Antihypertensive Agent that Antagonizes the Prohypertensive Effect of Endogenous Ouabain and Adducin
Cardiovascular & Hematological Agents in Medicinal Chemistry Protein disulfide isomerase and Nox: new partners in redox signaling
Current Pharmaceutical Design Low Molecular Weight Compounds with Transition Metals as Free Radical Scavengers and Novel Therapeutic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry Bioactive Peptides - Are There More Antihypertensive Mechanisms Beyond ACE Inhibition?
Current Pharmaceutical Design Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
Current Pharmaceutical Design Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Repeated Restraint and Nerve Growth Factor Administration in Male and Female Mice: Effect on Sympathetic and Cardiovascular Mediators of the Stress Response
Current Neurovascular Research Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets The Effects of Angiotensin II Signaling Blockade on Platelet Activity in Subjects with Hypertension
Current Hypertension Reviews Calixarene: A Versatile Material for Drug Design and Applications
Current Pharmaceutical Design Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management
Current Vascular Pharmacology Epidemiology and Management of Acute Kidney Injury in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization
Current Protein & Peptide Science The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia
Current Pharmaceutical Biotechnology The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design ACE Inhibitors for the Treatment of Hypertension Drug Selection by Means of the SOJA Method
Reviews on Recent Clinical Trials The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery (Discontinued)